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Background: Lack of patient involvement in decision making has been suggested as one reason for limited
treatment success. Concepts such as shared decision making may contribute to high quality healthcare by
supporting patients to make informed decisions together with their physicians.
A multi-component shared decision making programme on the prevention of heart attack in type 2 diabetes has
been developed. It aims at improving the quality of decision-making by providing evidence-based patient
information, enhancing patients’ knowledge, and supporting them to actively participate in decision-making. In this
study the efficacy of the programme is evaluated in the setting of a diabetes clinic.
Methods/Design: A single blinded randomised-controlled trial is conducted to compare the shared decision
making programme with a control-intervention. The intervention consists of an evidence-based patient decision aid
on the prevention of myocardial infarction and a corresponding counselling module provided by diabetes
educators. Similar in duration and structure, the control-intervention targets nutrition, sports, and stress coping. A
total of 154 patients between 40 and 69 years of age with type 2 diabetes and no previous diagnosis of ischaemic
heart disease or stroke are enrolled and allocated either to the intervention or the control-intervention. Primary
outcome measure is the patients’ knowledge on benefits and harms of heart attack prevention captured by a
standardised knowledge test. Key secondary outcome measure is the achievement of treatment goals prioritised by
the individual patient. Treatment goals refer to statin taking, HbA1c-, blood pressure levels and smoking status.
Outcomes are assessed directly after the counselling and at 6 months follow-up. Analyses will be carried out on
intention-to-treat basis. Concurrent qualitative methods are used to explore intervention fidelity and to gain insight
into implementation processes.
Discussion: Interventions to facilitate evidence-based shared decision making represent an innovative approach in
diabetes care. The results of this study will provide information on the efficacy of such a concept in the setting of a
diabetes clinic in Germany.
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Cardiovascular disease is the predominant life threatening
complication associated with type 2 diabetes. An array of
behavioural directives, such as quitting smoking, increas-
ing exercise, normalising weight, and adhering to monitor-
ing, dietary and medication prescriptions is imposed on
patients with type 2 diabetes. Evidence on efficacy of these
measures is varying and some may even do more harm
than good [1]. Patients frequently feel demotivated and
overloaded by the plethora of medical prescriptions. This
might contribute to poor long-term adherence [2,3] even
to the most effective preventative interventions such as
blood pressure control [4] and use of statins [5].
International and national societies claim a “patient cen-
tred approach” such as shared decision making (SDM) in
diabetes care [6,7]. SDM [8] implicates an “involvement of
both the patient and the doctor, sharing of information by
both parties, taking steps to build a consensus about the
preferred treatment, and reaching an agreement about
which treatment to implement” [9]. A prerequisite for an
informed decision making process is evidence-based pa-
tient information [8,10]. In Germany however, SDM has
not yet been implemented in diabetes care. Current educa-
tion and counselling programmes for patients with diabetes
provide rather general information, without numerical and
comparative risk information [11-14].
Key objective of this project is to improve the quality
of decision-making by enhancing patients’ understand-
ing and supporting them to actively deliberate between
the available treatment options. This approach is impli-
cated by the theory of planned behaviour [15], according
to which behaviour is influenced by attitudes, by subject-
ive norms such as perceived physicians’ attitudes, and by
perceived and actual individual behaviour control. Pro-
viding evidence-based information aims at strengthening
behaviour control by resolving knowledge deficits. Infor-
mation about probabilities of outcomes is tailored to in-
dividual risk to realign unrealistic expectations.
An informed shared decision making (ISDM) programme
on the prevention of heart attack in type 2 diabetes has
been developed [16,17]. In terms of a complex interven-
tion [18], it includes a number of interdependent com-
ponents that may interact with contextual factors such
as the educational background of participants and the
setting. Development and evaluation of these components
encompassed theoretical and empirical groundwork fo-
cusing on in-depth understanding of contextual interac-
tions and implementation processes. Details are published
elsewhere [16,17,19-21].
Key component of the ISDM-programme is an evidence-
based patient decision aid (DA) [17]. The DA comprises
decision relevant information on the concept of benefits
and harms of different preventative options, an individual
risk assessment tool, and a guide to support the decisionmaking process. A preliminary qualitative study with dia-
betes educators and patients [17] indicated good accept-
ance and suitability to support informed decision making.
Implementation of the DA is considered as optimal within
patient education curricula and counselling programmes.
Therefore, a patient counselling module was developed
[16] related to the DA (updated 08/2012) and based on
current criteria of evidence-based patient information [10].
In order to simplify implementation, duration and struc-
ture have been adapted to current patient education mod-
ules [11,12]. The counselling module was piloted within
the target group and iteratively optimised [16]. In order to
enable diabetes educators to successfully apply the coun-
selling, a train-the-trainer module has been developed,
consisting of a video with examples and instructions, and
a structured training-session.
Since piloting of the components of the ISDM
programme demonstrated feasibility and acceptance, evalu-
ation of the efficacy of the programme in a randomised-
controlled trial (RCT) is required prior to implementation
[18]. In addition, concurrent qualitative research is needed
to monitor and to ensure reliability and validity of the
intervention [22].
The reporting of this study follows current statements
[23-25].
Objectives
Primary objective is to investigate if the ISDM programme
is superior to the control-intervention regarding patients’
knowledge and realistic expectations concerning benefits
and harms of the available treatment options. Key second-
ary objective is to determine if patients in the ISDM group
achieve their individual treatment goals better than pa-
tients in the control-group. Additional objectives are to
assess if patients presenting high numeracy levels achieve
better knowledge than patients presenting low numeracy,
if social status correlates to the level of knowledge, and if
patients with good knowledge achieve their treatment
goals better than patients with poor knowledge.
Methods
Design
A parallel group, two-arm, single blinded, randomised-
controlled, superiority trial with 6 months follow-up is
conducted under high fidelity intervention conditions
[22] comparing the ISDM programme with a control-
intervention. Concurrent qualitative methods are used
to explore and promote intervention fidelity [22] and
to achieve in-depth understanding of implementation
processes.
Setting
Study site is the diabetes clinic at the Department for Endo-
crinology and Metabolic Diseases of the Jena University
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by diabetes educators and physicians usually twice but
at least once a year. Most patients have joined a struc-
tured treatment and teaching schedule within the disease
management programme (DMP). Four diabetes educators
guide, motivate, and coach the patients in individual and
group counselling sessions. Integral to the multidisciplinary
diabetes care team, the educators develop individual plans
of care, provide on-going self-management support, and
analyse and adapt diet-sheets and insulin dosages. Patient
characteristics, diagnoses, laboratory parameters, and pre-
scriptions are documented in an electronic patient record
system (EPRS).
Eligibility and recruitment
Patients with type 2 diabetes between 40 and 69 years of
age are eligible for enrolment if they have no previous
diagnosis of ischaemic heart disease (ICD I20-I25) or
stroke (ICD I63) and have participated in the DMP edu-
cation programmes for patients with type 2 diabetes. Pa-
tients are eligible with HbA1c-values between 6 and 9%.
This range of values is sensitive to patient participation
in decision making, regarding micro-vascular prevention.
Patients are excluded if they have proliferative retinop-
athy, chronic kidney disease stage 3 or higher [26], meta-
static cancer, or are addicted to alcohol or cared by a
legal guardian.
EPRS is screened for eligible patients (study flow Figure 1).
Those are asked to participate during their regular consult-
ation. The first patient was enrolled in March 2013. Esti-
mated completion of recruitment is December 2013.
Randomisation and blinding
Randomisation is performed in blocks of 8 to ensure close
balance of numbers of participants in each group and suf-
ficient numbers of participants (n = 4) in each counselling
session. Randomisation sequence is generated independ-
ently by the Centre for Clinical Studies at the Jena Univer-
sity Hospital.
Patients are blinded to study group allocation. Alloca-
tion is concealed during data entry and analysis.
Study interventions
Intervention group (ISDM programme)
The intervention (Table 1) comprises a decision aid book-
let [17] and a corresponding counselling module. The
counselling is provided by diabetes educators of the par-
ticipating clinic. Patients are guided through the decision
making process, by 1) jointly assessing the patient’s indi-
vidual heart attack risk, 2) providing outcome probabilities
of the available preventative treatment options, and 3)
supporting to set individual goals regarding smoking ces-
sation, glucose control, blood pressure control, and statintreatment. A physician is to be consulted if patients wish a
change of treatment regimens.
The counselling module takes about 90 minutes. Pa-
tients are asked to read and work through the DA, at
least one week before the group counselling session.
For study purposes, two diabetes educators have at-
tended the ISDM programme specific train-the-trainer
module given by a research fellow of the Unit of Health
Sciences and Education of the University of Hamburg.
In order to ensure educational fidelity, certified diabetes
educators provide the counselling sessions. To ensure fi-
delity of the evidence-based contents, the sessions are
videotaped and analysed. If required, the research fellow
gives feedback for optimisation.
Control group
Framing, duration and structure of the control-intervention
are similar to the ISDM intervention (Table 1). In contrast
to the ISDM intervention, participants are guided through
a counselling session about nutrition, sports, and stress
coping. The session ends after a take home relaxation exer-
cise. At least one week before the session, all participants
receive a brochure on stress management offered by health
insurances [27].
Outcomes
Primary outcome measure (Table 2) is the level of patient
knowledge relating to the concept of risk, the notion of
heart attack risk, and the benefits and harms of preventa-
tive treatment. Knowledge is captured by a standardised
questionnaire consisting of 12 questions to assess compre-
hension of risk information and realistic expectations [28],
plus one question to assess numeracy [29].
Secondary outcome measures comprise 1) sustainability
of knowledge; 2) achievement of individual treatment
goals regarding the use of statins, levels of blood pressure
and glucose control, and smoking; 3) achievement of
treatment goals prioritised by the individual patients; 4)
medication uptake from T1 to T2.
Data collection
The EPRS of the clinic and standardised forms are used to
collect baseline characteristics and outcome measures.
Baseline characteristics include age, gender, first-
language, social status [31], smoking status, blood pressure,
LDL-cholesterol, total cholesterol, HbA1c, current medica-
tion, and previous participation in diabetes patient educa-
tion programmes.
Baseline risks of myocardial infarction are calculated
by using a risk assessment tool based on age, smoking
status, and clinical parameters. The tool is derived from
the Framingham function and calibrated [32] to the
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Figure 1 Study flow.
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session and at 6 months follow-up. The individual treat-
ment goals regarding smoking cessation, glucose control,
blood pressure control, and statin treatment are assessed
after the counselling session. Achievement of treatment
goals is assessed during a consultation at 6 months follow-up. Current medication is monitored by verifying patients’
pill-packages. Smoking status is assessed by using a
standardised interview question. Current blood pressure
values (mean of 2 weeks) are extracted from patient dia-
ries. If values are not available, blood pressure is measured
before counselling by a nurse applying a standardised
Table 1 Characteristics of intervention and
control intervention
ISDM programme Control-intervention
Components Decision aid booklet “On
the prevention of heart
attack in type 2 diabetes” [17]
Brochure “Stress” [27]
Curriculum Curriculum
Media: Specific wall charts,
worksheets, question cards,




Duration 60-90 minutes 60-90 minutes
Group size 4 participants 4 participants
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trol is assessed by measuring HbA1c-levels [33].
Data synthesis
All statistical analyses are carried out according to the
intention-to-treat principle. Missing data will be imputed
using the method of multiple imputation if feasible. All
analyses will be computed using IBM SPSS Statistics
19.0 for Windows.
Baseline characteristics are described using means of
standard deviation (± SD) or frequencies, as appropriate
according to the level of measurement.
Primary outcome
Unpaired t-tests will be used to compare mean scores
of knowledge and realistic expectations directly after
counselling.
Secondary outcomes
Unpaired t-tests will be used to compare mean know-
ledge scores at follow-up. Fisher’s exact test will be usedTable 2 Data collection
Outcomes Measures
Knowledge • Questionnaire developed on the ba
and evidence-based information on
type 2 diabetes [17] (updated 08/201
Realistic expectations • Questionnaire developed on the ba
Numeracy • Numeracy test (one minute test for
Treatment goals • Statin medication, levels of blood p
smoking, and patient’s prioritized tre
documented on a standardised form
Achievement of treatment goals • Statin medication (patient medicati
• Blood pressure (self-monitoring, stand
• HbA1c-level (standardised measure
• Smoking cessation (question by dia
Medication • Variation in medication intake (stat
glucose-lowering agents) are docum
(T1) and by verifying patients’ pill-pa
* T1; at the end of the counselling session; T2; at 6 months follow-up.
** 6 out of 13 questions of the knowledge test.
*** 1 out of 13 questions of the knowledge test.to compare proportions of sufficient knowledge after coun-
selling and at follow-up. Participants will be rated as having
sufficient knowledge if they correctly answered at least 8
out of 12 questions. Unpaired t-tests will be used to com-
pare average individual differences between planned and
achieved values of blood pressure and HbA1c. Fisher’s exact
tests will be used to compare the groups regarding rates of
individual goal achievement (yes/no): statin choice, smoking
status, blood-pressure (defined as reaching 80% to 120% of
the goal), and HbA1c (defined as reaching 80% to 120% of
the goal). Mann Whitney U-Test will be used to compare
the medication uptake from T1 to T2 (increase/unchanged/
decrease).
Sub-group analyses
Two groups of participants will be defined regarding their
level of knowledge (sufficient / insufficient). Fisher’s exact
tests will be used to assess if knowledge is associated with
the level of numeracy (yes/no) and with achievement of
goals (yes/no). T-test for paired samples will be used to as-
sess differences in knowledge between T1 and T2 in the
intervention group. Analyses of variance (ANOVA) will be
used to assess if knowledge is associated with age (groups
40–49; 50–59; 60–69). Spearman’s Rho correlation coeffi-
cient will be used to assess if knowledge is associated with
social status.
Mann Whitney U-tests will be calculated to assess if
heart attack risk and social status are associated with the
achievement of goals (yes/no).
Sample size
We hypothesise patients in the ISDM group to reach
higher levels of knowledge and realistic expectations. BasedNo. of items Follow-up*
sis of Bloom’s taxonomy [30]
heart attack prevention in
2)
13 T1, T2
sis of ISDM-counselling 6** T1, T2
general population) [29] 1*** T1
ressure and glucose control,
atment goal are
1 for each goal T1
on boxes) 1 T2
ardised measure if not available) 1 T2
) 1 T2
betes educator) 1 T2
ins, antihypertensive drugs,
ented using medical records
ckages (T2).
3 T1, T2
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of the knowledge test, we estimate that participants having
received the intervention will reach 70% correct answers in
the knowledge test, whereas those having received the
control-intervention will reach 50% correct answers. We
calculate the sample size providing 80% power to detect an
absolute difference of 20% between the intervention and
the control group, using a two-tailed t-test at the 5% level
of significance. Estimating a standard deviation (SD) of 0.4
in both groups, data on about 64 patients per group (128
participants) need to be included in data-analysis. Estimat-
ing a non-responder/drop-out rate of about 15%, 154 par-
ticipants will need to be recruited for randomisation.
Intervention fidelity and process evaluation
The efficacy of the ISDM programme may depend on the
complex interaction between components (e.g. provider
training and patient counselling strategies) and terms and
conditions of the setting. Strategies to monitor and pro-
mote intervention fidelity [22] focus on study-design, pro-
vider training, delivery and receipt of intervention, and
enactment of treatment skills (Table 3).
Underlying processes are monitored to explore why the
intervention has worked or not. Video-taped counsellingTable 3 Intervention fidelity strategies
Category [22] Goals [22]
Design of study • Ensure same treatment dose within condition
• Ensure equivalent dose across conditions.
• Plan for implementation setbacks
Training providers • Standardize training
• Ensure provider skill acquisition
• Minimize “drift” in provider skills
• Accommodate provider differences (adequate lev
training, skills, experience and professional backgro
Delivery of intervention • Control for provider differences
• Reduce differences within treatment
• Ensure adherence to protocol
• Minimize contamination between conditions
Receipt of intervention • Ensure participant knowledge
• Ensure participant ability to use cognitive skills
• Ensure participant ability to perform behavioural
Enactment of
treatment skills
• Ensure participant use of cognitive skills
• Ensure participant use of behavioural skillssessions are constantly analysed and fed back to maintain
and optimise the fidelity of education and contents.
Ethical approval
The study protocol was approved by the ethics commit-
tee of the Jena University Hospital. Written participant
information about study objectives and procedures are
given to eligible patients. Standardised forms are used to
document informed consent.
Confidentiality
In order to maintain data privacy, pseudonyms are used
to combine data sets (baseline and follow-up data) and
to identify data if patients withdraw informed consent.
The pseudonym list is kept under lock at the Jena
University Hospital. Participant information is kept in
locked file cabinets. Computer files are code-locked to
prohibit unauthorized access.
Discussion
The planned study aims to determine the efficacy of a
complex counselling programme [16] regarding patient
knowledge, realistic expectations and achievement of indi-
vidual treatment goals. The used approach is innovative:Elements of the ISDM study
s. • Curriculum and media are standardised for both study arms
• Intervention and control-intervention are similar in framing,
duration and structure
• For both intervention and control-intervention, two diabetes
educators are trained to ensure the completion of the
counselling sessions
• All diabetes educators are trained in standardised
train-the-trainer sessions
• Educational material is standardised
• Optimal patient counselling is demonstrated
el of
und)
• Providers practise counselling under supervision of a
research fellow and subsequent feedback
• Providers assess the patient knowledge questionnaire
to ensure skill acquisition
• Counselling sessions are video-taped, constantly analysed,
and fed back by a research fellow
• Counselling protocol: deviation from curriculum
(duration, material use, content, didactics) is documented
• Questionnaire cards at the end of the counselling session.
If there are difficulties in understanding, the diabetes educator
discusses and corrects the answer and repeats the information
skills
• Patients set individual treatment goals for heart attack prevention
• If patients make treatment decisions that differ from their current
treatment goals a physician is consulted for clarification
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tient information on heart attack risk and prevention, dis-
cuss the individual notion of that information, and initiate
a shared decision making process. Patients are motivated
to set individual goals choosing the treatment options
most important to them.
The study is conducted in the context of a diabetes out-
patient clinic, which allows high standardization to moni-
tor and maintain intervention fidelity. Moreover, qualitative
methods are used to explore processes and barriers of im-
plementation. A corresponding cluster-RCT is planned to
assess the effectiveness of the ISDM-programme in the set-
ting of primary care-practices.
Abbreviations
DA: Decision aid; DMP: Disease management programme; EPRS: Electronic
patient record system; ICD: International classification of diseases;
ISDM: Informed shared decision making; RCT: Randomised controlled trial;
SDM: Shared decision making.
Competing interests
The authors (SB, TH, JK, IM, UAM, TL and ML) declare that they have no
competing interests.
Authors’ contributions
This study protocol was carried out in collaboration between all authors. SB,
JK, ML and IM are involved in the study design. TH and UAM are involved in
the planning, coordination and management of data acquisition at study site
(diabetes out-patient clinic). TL has contributed to the statistical planning of
the study. SB and ML wrote the first draft of the manuscript. IM, JK, TH, and
UAM substantially contributed to the draft of the manuscript. IM and JK
critically revised the manuscript. ML, JK, UAM and IM conceived the study
and applied for funding. All authors have read and approved the final
version of the manuscript.
Authors’ information
SB is research fellow at the MIN Faculty, Unit of Health Sciences and
Education, University of Hamburg, Germany. ML and JK are senior
researchers at the MIN Faculty, Unit of Health Sciences and Education,
University of Hamburg, Germany. IM is Professor of Health Sciences and
Education, University Hamburg, Germany, and specialist in Internal Medicine,
Diabetology and Endocrinology.
TH is a research fellow at the Department for Internal Medicine,
Endocrinology and Metabolic Diseases in Jena, Germany. TL is biostatistician
at the Centre for Clinical Studies of the Jena University Hospital. UAM is
Professor for internal medicine and head of the Department for
Endocrinology and Metabolic Diseases of the Jena University Hospital.
Acknowledgement
We thank Nicolle Müller PhD, Benjamin Milke, and Guido Kramer for their
valuable support regarding the planning of data acquisition at study site.
Source of funding
The study is funded by the European Foundation for the Study of Diabetes
(EFSD) on behalf of the European Association for the Study of Diabetes (EASD).
Author details
1Unit of Health Sciences and Education, Hamburg University,
Hamburg, Germany. 2Department of Internal Medicine III,
Endocrinology and Metabolic Diseases, Jena University Hospital, Jena,
Germany. 3Institute for Neuroimmunology and Clinical MS Research,
University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
4Department of Primary Medical Care, University Medical Centre
Hamburg-Eppendorf, Hamburg, Germany. 5Centre for Clinical Studies,
Jena University Hospital, Jena, Germany.Received: 8 October 2013 Accepted: 16 October 2013
Published: 19 October 2013References
1. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC,
Genuth S, Ismail-Beigi F, Grimm RH Jr, et al: Effects of intensive glucose
lowering in type 2 diabetes. NEJM 2008, 358(24):2545–2559.
2. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X: Interventions for
enhancing medication adherence. Cochrane Database Syst Rev 2008,
2:CD000011.
3. Schedlbauer A, Davies P, Fahey T: Interventions to improve adherence to
lipid lowering medication. Cochrane Database Syst Rev 2010, 3:CD004371.
4. U. K. Prospective Diabetes Study Group: Tight blood pressure control and
risk of macrovascular and microvascular complications in type 2
diabetes: UKPDS 38. BMJ 1998, 317(7160):703–713.
5. Costa J, Borges M, David C, Vaz CA: Efficacy of lipid lowering drug
treatment for diabetic and non-diabetic patients: meta-analysis of
randomised controlled trials. BMJ 2006, 332(7550):1115–1124.
6. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M,
Peters AL, Tsapas A, Wender R, Matthews DR: Management of
hyperglycaemia in type 2 diabetes: a patient-centered approach.
Position statement of the American Diabetes Association (ADA) and the
European Association for the Study of Diabetes (EASD). Diabetologia
2012, 55(6):1577–1596.
7. German Medical Association, National Association of Statutory Health
Insurance Physicians, Association of the Scientific Medical Societies: National
Disease Management Guidelines Programme: Typ-2-Diabetes mellitus -
Therapy; 2013. Available from: http://www.versorgungsleitlinien.de/themen/
diabetes2/dm2_therapie/pdf [Accessed 07th Oct 2013].
8. Edwards A, Elwyn G: Shared decision making in health care: achieving evidence
based patient choice. 2nd edition. Oxford: Oxford University Press; 2009.
9. Charles C, Gafni A, Whelan T: Shared decision-making in the medical
encounter: what does it mean? (or it takes at least two to tango).
Soc Sci Med 1997, 44(5):681–692.
10. Bunge M, Mühlhauser I, Steckelberg A: What constitutes evidence-based
patient information? Overview of discussed criteria. Patient Educ Couns
2010, 78(3):316–328.
11. Kronsbein P, Mühlhauser, Jörgens V, Scholz V, Venhaus A, Berger M:
Evaluation of a structured treatment and teaching programme on non-
insulin-dependent diabetes. Lancet 1988, 2(8625):1407–1411.
12. Müller UA, Müller R, Starrach A, Hunger-Dathe W, Schiel R, Jörgens V, Grüßer M:
Should insulin therapy in type 2 diabetic patients be started on an out- or
inpatient basis? Results of a prospective controlled trial using the same
treatment and teaching programme in ambulatory care and a university
hospital. Diabetes Metab 1998, 24(3):251–255.
13. Hermanns N, Kulzer B, Maier B, Mahr M, Haak T: The effect of an education
programme (MEDIAS 2 ICT) involving intensive insulin treatment for
people with type 2 diabetes. Patient Educ Couns 2012, 86(2):226–232.
14. Kulzer B, Hermanns N, Reinecker H, Haak T: Effects of self-management
training in Type 2 diabetes: a randomized, prospective trial. Diabet Med
2007, 24(4):415–423.
15. Ajzen I: The theory of planned behaviour. Org Behav Hum Decis Process
1991, 50:179–211.
16. Buhse S, Michalzik E, Kasper J, Mühlhauser I, Lenz M: [Development and
piloting of an informed shared decision making programme on the prevention
of myocardial infarction in type 2 diabetes]. Berlin: 14. Congress of the
German Network for Evidence Based Medicine; 2013. Available from: http://
www.egms.de/static/de/meetings/ebm2013/13ebm090.shtml [Accessed
07th Oct 2013].
17. Lenz M, Kasper J, Mühlhauser I: Development of a patient decision aid for
prevention of myocardial infarction in type 2 diabetes - rationale, design
and pilot testing. Psychosoc Med 2009, 6:Doc05.
18. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M:
Developing and evaluating complex interventions: the new Medical
Research Council guidance. BMJ 2008, 337:a1655.
19. Lenz M, Kasper J, Mühlhauser I: Searching for diabetes decision aids and
related background information. Diabet Med 2006, 23(8):912–916.
20. Lenz M, Mühlhauser I: Cardiovascular risk assessment for informed
decision making. Validity of prediction tools. Med Klin (Munich) 2004,
99(11):651–661.
Buhse et al. BMC Family Practice 2013, 14:155 Page 8 of 8
http://www.biomedcentral.com/1471-2296/14/15521. Lenz M, Mühlhauser I: Decision aids in diabetes. In Shared decision making
in health care: achieving evidence based patient choice. 2nd edition. Edited
by Edwards A, Elwyn G. Oxford: Oxford University Press; 2009:285–295.
22. Bellg AJ, Borrelli B, Resnick B, Hecht J, Minicucci DS, Ory M, Ogedegbe G,
Orwig D, Ernst D, Czajkowski S: Enhancing treatment fidelity in health
behavior change studies: best practices and recommendations from the
NIH behavior change consortium. Health Psychol 2004, 23(5):443–451.
23. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P: Methods and
processes of the CONSORT Group: example of an extension for trials
assessing nonpharmacologic treatments. Ann Intern Med 2008,
148(4):W60–W66.
24. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, Dickersin
K, Hrobjartsson A, Schulz KF, Parulekar WR, et al: SPIRIT 2013 explanation
and elaboration: guidance for protocols of clinical trials. BMJ 2013,
346:e7586.
25. Möhler R, Bartoszek G, Köpke S, Meyer G: Proposed criteria for reporting
the development and evaluation of complex interventions in healthcare
(CReDECI): guideline development. Int J Nurs Stud 2012, 49(1):40–46.
26. National Kidney Foundation (KDOQI): Clinical Practice Guideline for
Diabetes and Chronic Kidney Disease: 2012 Update. Am J Kidney Dis 2012,
60(5):850–886.
27. Vollmer-Rupprecht R: Stress. Hamburg: Techniker Krankenkasse; 2013.
Available from: http://www.tk.de/centaurus/servlet/contentblob/48660/
Datei/63352/TK-Broschuere-Der-Stress.pdf [Accessed 07th Oct 2013]
28. O’Connor AM: User Manual – Realistic Expectations. Ottawa: Ottawa Hospital
Research Institute; 1995 [modified 2002], 6 p. Available from http://
decisionaid.ohri.ca/docs/develop/User_Manuals/UM_Realistic_Expectations.
pdf [Accessed 07th Oct 2013].
29. Cokely ET, Galesic M, Schulz E, Ghazal S, Garcia-Retamero R: Measuring risk
literacy: The Berlin Numeracy Test. Judgm Decis Mak 2012, 7:25–47.
30. Anderson LW, Krathwohl DR: A taxonomy for learning, teaching, and
assessing: a revision of Bloom’s taxonomy of educational objectives. New York:
Longman; 2001.
31. Dulon M, Bardehle D, Blettner M: [Assessing social inequality in
microcensus data and German national health examination survey].
Gesundheitswesen 2003, 65(11):629–635.
32. Hense HW, Schulte H, Lowel H, Assmann G, Keil U: Framingham risk
function overestimates risk of coronary heart disease in men and
women from Germany - results from the MONICA Augsburg and the
PROCAM cohorts. EurHeart J 2003, 24(10):937–945.
33. Tosoh Bioscience Inc: G8 90SL HPLC Analyzer. South San Francisco, CA;
2008:94080.
doi:10.1186/1471-2296-14-155
Cite this article as: Buhse et al.: An evidence-based shared decision
making programme on the prevention of myocardial infarction in type
2 diabetes: protocol of a randomised-controlled trial. BMC Family Practice
2013 14:155.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
